Enhance your patent search with AI. Try the FREE AI-powered tool

COVID-19 Vaccine Candidates: A Closer Look at Pfizer, Moderna, and AstraZeneca

image that illustrates the patent landscape report for vaccines

COVID-19 Vaccine Candidates: A Closer Look at Pfizer, Moderna, and AstraZeneca

The COVID-19 vaccine market is expected to be valued at $10 billion a year across developed countries based on analyst estimates from Morgan Stanley and Credit Suisse. An analyst from Credit Suisse even expects that the market could be worth more than $10 billion in the United States alone. In recent news, vaccine candidates from Pfizer-BioNTech, Moderna, and Oxford-AstraZeneca have shown high efficacy rates, with Pfizer leading the pack as it obtained approval from the UK and Canada for mass rollout. The COVID-19 vaccine race might be already declaring its frontrunners in the coming months, and we deem it necessary to look at the patent landscape these pharma giants are operating in.

Know the landscape. Get ahead.

Get customized, comprehensive patent landscape reports on your chosen technology area.

Subscribe to our newsletter

  • Questions? Check our privacy policy.
  • This field is for validation purposes and should be left unchanged.

Sign up to get access

"*" indicates required fields

Name*
By signing, you accept Parola Analytics terms of service and privacy policy, and agree to receive occasional email about campaigns. you can unsubscribe anytime.
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Patent and IP updates straight to your inbox

Sign up now to receive monthly patent news, analysis and free insight reports.

We don’t spam, we promise.

Disclaimer: 

1. Parola Analytics and Avontis are distinct entities and operate independently. Any references to Avontis or its services do not constitute a legal partnership. 

2. Parola Analytics does not provide legal services. Our services are limited to research and technical analysis. Any information provided by Parola Analytics should not be construed as legal advice.